- Oculis’ eye drops for diabetic macular edema flunk Phase 3 testOculis saw its stock plummet after reporting that its investigational eye drops for diabetic macular edema (DME) did not succeed in a pair of Phase 3 trials. After a year, its eye drop called OCS…Endpoints · 1mo ago↗ source
- #ASCO26: Yes, Revolution Medicines' pancreatic cancer data are that goodCHICAGO — When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News.…Endpoints · 1mo ago↗ source
- #ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer studyCHICAGO — The leading drug in biopharma's hottest immunotherapy race reduced the risk of death by 34% in previously untreated Chinese lung cancer patients, compared to standard immunotherapy plus c…